Key result
Akt-engineered mesenchymal stem cells reduce infarct size and restore early cardiac function without cell fusion.
We previously reported that intramyocardial injection of bone marrow-derived mesenchymal stem cells overexpressing Akt (MSC-Akt) efficiently repaired infarcted rat myocardium and improved cardiac function. Controversy still exists over the mechanisms by which MSC contribute to tissue repair. Herein, we tested if cellular fusion of MSC plays a determinant role in cardiac repair. We injected MSC expressing Cre recombinase, with or without Akt, into Cre reporter mice. In these mice, LacZ is expressed only after Cre-mediated excision of a loxP-flanked stop signal and is indicative of fusion. MSC engraftment within infarcted myocardium was transient but significantly enhanced by Akt. MSC fusion with cardiomyocytes was observed as early as 3 days, but was infrequent, and we found a low rate of differentiation of MSC into cardiomyocytes. MSC-Akt decreased infarct size at 3 days and restored early cardiac function. In conclusion, MSC-Akt improved early repair despite transient engraftment, low levels of cellular fusion, and differentiation. These new observations further confirm our recently reported data that early paracrine mechanisms mediated by MSC are responsible for enhancing the survival of existing myocytes and that Akt could alter the secretion of various cytokines and growth factors.
No takes yet. Share an insight, caveat, or question.
Noiseux et al. (2006) studied Myocardial infarction. Mesenchymal stem cells overexpressing Akt (MSC-Akt) vs. Mesenchymal stem cells without Akt was evaluated on Infarct size, cardiac function, and cellular fusion. Mesenchymal stem cells overexpressing Akt decreased infarct size at 3 days and restored early cardiac function in infarcted mice despite infrequent cellular fusion or differentiation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: